Meta-analysis finds higher AEA and PEA in depression, but not 2-AG or OEA

Neuroimmune lipidome dysregulation in major depressive disorder: A meta-analysis of peripheral endocannabinoid and N-acylethanolamine signaling.

Brain, behavior, and immunity • • Meta-Analysis • Highly Relevant
🤖

AI Summary

This systematic review and meta-analysis asked whether circulating endocannabinoids and related N-acylethanolamines differ between people with major depressive disorder (MDD) and healthy controls. It combined 9 observational studies, covering 514 people with MDD and 417 controls. The main finding was that people with MDD had significantly higher blood levels of anandamide (AEA) and palmitoylethanolamide (PEA); the analysis found no significant differences in 2-AG or oleoylethanolamide (OEA).

Subgroup analyses found that the AEA elevation was more pronounced among medicated patients and people with psychiatric comorbidities. These results suggest selective differences in endocannabinoid-related lipid signaling in MDD, but do not show that those differences cause depression or that the molecules are useful clinical biomarkers. Because this is an abstract-based summary of existing studies, and treatment and comorbidities may influence the findings, longitudinal and mechanistic research is needed to clarify their significance.

💡 Key Findings

1
Across 9 observational studies, circulating anandamide (AEA) was significantly higher in people with MDD than in healthy controls.
High
90%
2
Circulating palmitoylethanolamide (PEA) was also significantly higher in people with MDD than in controls.
High
90%
3
The meta-analysis found no significant differences in circulating 2-AG or oleoylethanolamide (OEA).
High
90%
4
AEA elevations were more pronounced among medicated patients and people with psychiatric comorbidities; the abstract notes these factors need further study and does not establish why the differences occur.
High
80%

📄 Original Abstract

Major depressive disorder (MDD) is a prevalent psychiatric condition characterized by substantial biological heterogeneity. Evidence suggests that the endocannabinoid system (ECS), which regulates stress responses, emotional processing, and neuroimmune signaling, may contribute to depression pathophysiology. However, clinical studies examining circulating endocannabinoids (eCBs) and N-acylethanolamines (NAEs) in MDD have produced inconsistent findings. We therefore conducted a systematic review and meta-analysis to quantify peripheral alterations in eCBs and NAEs in individuals with MDD. Following PRISMA guidelines, case-control and cross-sectional studies comparing circulating levels of eCBs and NAEs between patients with MDD and healthy controls were identified. Standardized mean differences (SMDs) with 95 % confidence intervals (CIs) were calculated using a random-effects model. Between-study heterogeneity was assessed by using Cochran's Q test and further explored in subgroups analysis. Nine studies, including 514 individuals with MDD and 417 healthy controls, met the inclusion criteria. Patients with MDD exhibited significantly higher circulating levels of anandamide (AEA; SMD = 0.32, 95 % CI: 0.10 - 0.54, p < 0.01) and palmitoylethanolamide (PEA; SMD = 0.35, 95 % CI: 0.04 - 0.65, p = 0.03) compared with controls, whereas no significant differences were observed for 2-arachidonoylglycerol (2-AG) or oleoylethanolamide (OEA). Subgroup analyses indicated that the elevation in AEA levels were more pronounced among medicated patients and individuals with psychiatric comorbidities. These findings suggest selective alterations in ECS-related lipid mediators in individuals with MDD and support dysregulation of the ECS-NAE signaling axis in depression. Circulating lipid signaling molecules such as AEA and PEA may represent potential peripheral biomarkers of MDD, although longitudinal and mechanistic studies are needed to clarify the influence of treatment and comorbidities.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.